TP 113

Drug Profile

TP 113

Alternative Names: TP-113

Latest Information Update: 12 Aug 2015

Price : $50

At a glance

  • Originator Thetis Pharmaceuticals
  • Class Biguanides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 12 Aug 2015 Thetis Pharmaceuticals has patent protection for TP 113 in USA (Thetis Pharmaceuticals website, August 2015)
  • 29 Apr 2015 Preclinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top